Metformin Nonbeneficial in High-Risk Nonmetastatic BC Patients Without Diabetes
In observational studies, the use of metformin in patients with type 2 diabetes has been inconsistently associated with beneficial effects on breast cancer (BC) prognosis. However, it is unclear whether metformin confers any protective effect in patients with BC who do not have diabetes. The purpose of this study was to determine whether the administration of adjuvant metformin in BC patients without diabetes improves outcomes. Read more.

Effects of Scalp Cooling in Breast Cancer Patients
Alopecia is one of the most dreaded adverse effects associated with the use of chemotherapy. It can adversely affect a patient's quality of life. In April 2017, the FDA approved scalp cooling as a method to try to reduce hair loss. Studies have produced mixed results as to the benefit of this practice for preventing hair loss in breast cancer patients. Read more.

Effects on Adjuvant and Neoadjuvant BC Treatments on Mortality
Numerous breast cancer (BC) treatment guidelines are available from the United States and Europe. However, these guidelines often lack direct quantitative estimates of the risk of adjuvant or neoadjuvant chemotherapy and radiation on mortality. Investigators conducted a systematic review of BC guidelines, focusing on the relative risk of different treatments that can contribute to BC–related or non-BC–related mortality. Read more.